Confusable diagnoses · PANCE / PANRE

Acute Myeloid Leukemia vs Chronic Myeloid Leukemia

Acute Myeloid Leukemia and Chronic Myeloid Leukemia are easy to mix up on the boards. Here's a side-by-side comparison — presentation, workup, imaging, and first-line treatment — drawn from our full outlines.

Acute Myeloid Leukemia vs Chronic Myeloid Leukemia at a glance

  • Acute Myeloid Leukemia: Clonal expansion of myeloid blasts in marrow and blood — pancytopenia plus circulating blasts; APL subtype is a hemorrhagic emergency.
  • Chronic Myeloid Leukemia: Myeloproliferative neoplasm defined by the Philadelphia chromosome (BCR-ABL1) — transformed by targeted TKI therapy into a chronic, manageable disease.

Try two board-style questions on Acute Myeloid Leukemia vs Chronic Myeloid Leukemia

Real questions from the FirstPassPA bank, with the full explanation. Pick an answer — no signup, no email.

Question 1HematologyMedium
A 67-year-old man is admitted with 3 weeks of progressive fatigue, dyspnea on exertion, gum bleeding, and several scattered bruises. Examination shows conjunctival pallor and petechiae over both shins. Laboratory studies show hemoglobin 7.6 g/dL, platelet count 18,000/µL, and an absolute neutrophil count of 400/µL. The peripheral smear shows numerous large myeloblasts, some containing eosinophilic needle-like cytoplasmic inclusions. Bone marrow biopsy reveals 65% myeloblasts. Which of the following best explains his anemia, thrombocytopenia, and neutropenia?
  • AIneffective hematopoiesis with intramedullary apoptosis of mature precursors
  • BMarrow crowding by proliferating myeloblasts suppressing normal hematopoiesis
  • CConsumptive coagulopathy depleting circulating platelets and clotting factors
  • DAutoantibody-mediated peripheral destruction of mature circulating blood cells
  • ESplenic sequestration of circulating mature erythrocytes and platelets
Reveal answer & full explanation
Correct answer: B — Marrow crowding by proliferating myeloblasts suppressing normal hematopoiesis
  • AIneffective hematopoiesis with intramedullary apoptosis of mature precursors
  • BMarrow crowding by proliferating myeloblasts suppressing normal hematopoiesis✓
  • CConsumptive coagulopathy depleting circulating platelets and clotting factors
  • DAutoantibody-mediated peripheral destruction of mature circulating blood cells
  • ESplenic sequestration of circulating mature erythrocytes and platelets

Why Marrow crowding by proliferating myeloblasts suppressing normal hematopoiesis is correct

  • In AML, acquired genetic/epigenetic lesions (e.g., FLT3, NPM1, CEBPA, IDH1/2) block myeloid differentiation while driving blast proliferation.
  • The expanding clone of myeloblasts fills the marrow space (here 65% blasts) and suppresses normal erythroid, megakaryocytic, and granulocytic production, producing the triad of anemia, thrombocytopenia, and neutropenia.
  • The needle-like inclusions are Auer rods, pathognomonic for AML and confirming a myeloid blast process.

Why the others are wrong

  • Autoantibody-mediated peripheral destruction of mature circulating blood cells is the mechanism of autoimmune cytopenias (immune thrombocytopenia, autoimmune hemolytic anemia); it does not produce a marrow packed with 65% myeloblasts.
  • Splenic sequestration of circulating mature erythrocytes and platelets occurs in hypersplenism, where peripheral pooling drives cytopenias but the marrow stays cellular with normal maturing lineages rather than blast-filled.
  • Ineffective hematopoiesis with intramedullary apoptosis of mature precursors describes myelodysplastic syndrome or megaloblastic anemia, where a hypercellular marrow shows dysplastic but maturing precursors and fewer than 20% blasts, not 65% blasts with Auer rods.
  • Consumptive coagulopathy depleting circulating platelets and clotting factors — gum bleeding, bruising, and Auer rods raise concern for disseminated intravascular coagulation, which complicates AML and especially acute promyelocytic leukemia, but consumption cannot cause neutropenia and does not account for trilineage cytopenias in a marrow replaced by 65% myeloblasts.
Question 2HematologyMedium
A 52-year-old man has fatigue and splenomegaly. WBC is 78,000 with left-shifted myeloid cells at all stages of maturation. Cytogenetics shows t(9;22)(q34;q11). Which molecular abnormality results from this translocation?
  • APML-RARA fusion
  • BFLT3-ITD mutation
  • CJAK2 V617F mutation
  • DBCR-ABL fusion
  • EAML1-ETO fusion
Reveal answer & full explanation
Correct answer: D — BCR-ABL fusion
  • APML-RARA fusion
  • BFLT3-ITD mutation
  • CJAK2 V617F mutation
  • DBCR-ABL fusion✓
  • EAML1-ETO fusion

Why BCR-ABL fusion is correct

  • Chronic myeloid leukemia (CML): t(9;22) creates the Philadelphia chromosome, fusing BCR (chr 22) with ABL1 (chr 9)
  • The resulting BCR-ABL fusion protein is a constitutively active tyrosine kinase that drives myeloid proliferation
  • Imatinib (Gleevec) and other tyrosine kinase inhibitors (dasatinib, nilotinib) bind the ATP-binding pocket of BCR-ABL, dramatically improving prognosis
  • CML has three phases: chronic, accelerated, and blast crisis

Why the others are wrong

  • PML-RARA fusion — PML-RARA results from t(15;17) and causes acute promyelocytic leukemia (APL) (AML M3); treated with all-trans retinoic acid (ATRA) + arsenic; carries risk of disseminated intravascular coagulation (DIC)
  • JAK2 V617F mutation — JAK2 V617F is associated with myeloproliferative neoplasms: polycythemia vera, essential thrombocythemia (ET), and primary myelofibrosis; treated with ruxolitinib
  • FLT3-ITD mutation — FLT3-ITD occurs in acute myeloid leukemia (AML) and confers poor prognosis; treated with midostaurin
  • AML1-ETO fusion — t(8;21) creates this fusion (now written RUNX1::RUNX1T1), a core-binding factor abnormality of acute myeloid leukemia (AML) with a relatively favorable prognosis; it does not arise from t(9;22), and AML presents with circulating blasts rather than the full spectrum of maturing myeloid cells seen in CML

That's 2 of 7,700+. Get the rest.

Unlock the full FirstPassPA bank: 7,700+ board-style questions, flashcards, and an AI tutor that explains every answer. Your 7-day free trial includes everything, and there's no credit card required.

Start your 7-day free trial →
🔒 Free preview limit reached

Keep comparing — start your free trial

You've used your 2 free previews. Create your free account to see the full Acute Myeloid Leukemia vs Chronic Myeloid Leukemia comparison — plus all 514 diagnosis outlines, 7,700+ board-style questions, and an AI tutor. Your 7-day free trial includes everything, no credit card required.

Free to start · No credit card · Cancel anytime

Side-by-side comparison

FeatureAcute Myeloid LeukemiaChronic Myeloid Leukemia
At a glanceClonal expansion of myeloid blasts in marrow and blood — pancytopenia plus circulating blasts; APL subtype is a hemorrhagic emergency.Myeloproliferative neoplasm defined by the Philadelphia chromosome (BCR-ABL1) — transformed by targeted TKI therapy into a chronic, manageable disease.
Classic presentationOlder adult with pancytopenia, fatigue, petechiae, and Auer rods on blast smear. APL: severe DIC with intracranial or pulmonary hemorrhage at presentation.; Pancytopenia symptoms: fatigue, dyspnea, pallor (anemia); easy bruising, petechiae, mucosal bleeding (thrombocytopenia); fever, recurrent infections (neutropenia); Constitutional:…Middle-aged adult with marked leukocytosis (often 100-500K), left-shifted granulocytosis with all stages of myeloid maturation, basophilia, and splenomegaly.; Often asymptomatic — diagnosed on incidental leukocytosis (~40-50% of cases); Fatigue, malaise, weight loss, low-grade fever, night sweats (constitutional symptoms); Early…
Workup / key labs≥20% myeloid blasts in bone marrow or peripheral blood (WHO 5th edition); or any blast percentage with recurrent cytogenetic abnormality t(15;17), t(8;21), inv(16)/t(16;16). APL diagnosed by t(15;17) PML-RARA or PML-RARA fusion.; CBC — anemia, thrombocytopenia; WBC may be high, normal, or low; circulating blasts often visible;…BCR-ABL1 fusion (by cytogenetics t(9;22), FISH, or PCR) in a patient with myeloproliferative features. Phase determined by blast count and clinical criteria.; CBC — marked leukocytosis (often 100-500K), thrombocytosis common, mild anemia variable; eosinophilia and BASOPHILIA characteristic; Peripheral smear — left-shifted…
ImagingCXR if pulmonary symptoms; chest CT for febrile neutropenia evaluation; Echocardiogram before anthracycline therapy; CT or MRI head if neurologic symptomsAbdominal exam / ultrasound to document spleen size; Echocardiogram baseline before nilotinib/ponatinib (cardiovascular risk)
First-line treatmentInduction chemotherapy '7+3': cytarabine (continuous infusion × 7 days) + anthracycline (daunorubicin or idarubicin × 3 days) — standard for fit patients; Addition of midostaurin for FLT3-mutated AML (RATIFY trial); gilteritinib for FLT3-mutated relapsed/refractory; Older or unfit patients: venetoclax (BCL-2 inhibitor) + hypomethylating…Tyrosine kinase inhibitor (TKI) — imatinib, dasatinib, nilotinib, bosutinib, or asciminib (first-line options; asciminib FDA-approved for newly diagnosed chronic phase in 2024); ponatinib for T315I mutation or failure of multiple TKIs; Imatinib (Gleevec) — first-generation, well-tolerated, long-term safety data; standard initial therapy…

Drill Acute Myeloid Leukemia vs Chronic Myeloid Leukemia questions on FirstPassPA

Turn this comparison into retention. 7,700+ board-style questions with an AI tutor that explains every answer — free to start, no card required.

Start your 7-day free trial → Get today's free question →

Educational use only. This outline is a study aid for PA students and is not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA or PAEA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants; End of Rotation™ is a program of the Physician Assistant Education Association.